Colorectal Cancer Incidence and Mortality After Negative Colonoscopy Screening Results.

IF 28.4 1区 医学 Q1 Biochemistry, Genetics and Molecular Biology Jama Oncology Pub Date : 2024-11-27 DOI:10.1001/jamaoncol.2024.5227
Markus Dines Knudsen, Kai Wang, Liang Wang, Georgios Polychronidis, Paula Berstad, Anette Hjartåker, Zhe Fang, Shuji Ogino, Andrew T Chan, Mingyang Song
{"title":"Colorectal Cancer Incidence and Mortality After Negative Colonoscopy Screening Results.","authors":"Markus Dines Knudsen, Kai Wang, Liang Wang, Georgios Polychronidis, Paula Berstad, Anette Hjartåker, Zhe Fang, Shuji Ogino, Andrew T Chan, Mingyang Song","doi":"10.1001/jamaoncol.2024.5227","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>The current recommendation for a 10-year rescreening interval after a negative colonoscopy screening (NCS) result has been questioned, with some studies showing a persistently lower risk of colorectal cancer (CRC) after NCS results.</p><p><strong>Objective: </strong>To examine long-term CRC incidence and mortality after NCS results (ie, no presence of CRC or polyps) and according to a risk score based on major demographic and lifestyle risk factors.</p><p><strong>Design, setting, and participants: </strong>In this cohort study, 3 prospective US population-based cohorts from the Nurses' Health Study, Nurses' Health Study II, and Health Professionals Follow-up Study were followed up from 1988 and 1991 to 2020. Data from the National Health and Nutrition Examination Survey (NHANES) from the January 1, 2017, to December 31, 2018, cycle were used to compare the risk profile distribution with that of the general US population. Data analysis was performed from October 2023 to August 2024.</p><p><strong>Exposures: </strong>Time-varying status of NCS results and risk score.</p><p><strong>Main outcomes and measures: </strong>Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% CIs for incidence and mortality of CRC.</p><p><strong>Results: </strong>A total of 195 453 participants (median [IQR] age, 44 [37-56] years at baseline; 81% female) were followed up for a median (IQR) of 12 (6-20) years. Among 81 151 individuals with NCS results and 114 302 without endoscopy, 394 and 2229 CRC cases and 167 and 637 CRC deaths, respectively, were documented. Negative colonoscopy screening results were consistently associated with lower CRC incidence (HR, 0.51; 95% CI, 0.44-0.58) and mortality (HR, 0.56; 95% CI, 0.46-0.70) for 20 years. Among individuals with NCS results, those with an intermediate risk (scores, 6-7) and low risk (scores, 0-5) did not reach the 10-year cumulative incidence of CRC (0.78%) of the high-risk individuals (scores, 8-12) until 16 and 25 years after initial screening, respectively.</p><p><strong>Conclusion and relevance: </strong>These findings provide evidence for shared decision-making between patients and physicians to consider extending the rescreening intervals after an NCS result beyond the currently recommended 10 years, particularly for individuals with a low-risk profile. These results showed, as a proof of concepts, the importance of considering known CRC risk factors when making decisions for colonoscopy rescreening.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jama Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2024.5227","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: The current recommendation for a 10-year rescreening interval after a negative colonoscopy screening (NCS) result has been questioned, with some studies showing a persistently lower risk of colorectal cancer (CRC) after NCS results.

Objective: To examine long-term CRC incidence and mortality after NCS results (ie, no presence of CRC or polyps) and according to a risk score based on major demographic and lifestyle risk factors.

Design, setting, and participants: In this cohort study, 3 prospective US population-based cohorts from the Nurses' Health Study, Nurses' Health Study II, and Health Professionals Follow-up Study were followed up from 1988 and 1991 to 2020. Data from the National Health and Nutrition Examination Survey (NHANES) from the January 1, 2017, to December 31, 2018, cycle were used to compare the risk profile distribution with that of the general US population. Data analysis was performed from October 2023 to August 2024.

Exposures: Time-varying status of NCS results and risk score.

Main outcomes and measures: Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% CIs for incidence and mortality of CRC.

Results: A total of 195 453 participants (median [IQR] age, 44 [37-56] years at baseline; 81% female) were followed up for a median (IQR) of 12 (6-20) years. Among 81 151 individuals with NCS results and 114 302 without endoscopy, 394 and 2229 CRC cases and 167 and 637 CRC deaths, respectively, were documented. Negative colonoscopy screening results were consistently associated with lower CRC incidence (HR, 0.51; 95% CI, 0.44-0.58) and mortality (HR, 0.56; 95% CI, 0.46-0.70) for 20 years. Among individuals with NCS results, those with an intermediate risk (scores, 6-7) and low risk (scores, 0-5) did not reach the 10-year cumulative incidence of CRC (0.78%) of the high-risk individuals (scores, 8-12) until 16 and 25 years after initial screening, respectively.

Conclusion and relevance: These findings provide evidence for shared decision-making between patients and physicians to consider extending the rescreening intervals after an NCS result beyond the currently recommended 10 years, particularly for individuals with a low-risk profile. These results showed, as a proof of concepts, the importance of considering known CRC risk factors when making decisions for colonoscopy rescreening.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结肠镜筛查结果阴性后的结直肠癌发病率和死亡率。
重要性:目前关于结肠镜筛查(NCS)阴性结果后 10 年再筛查间隔的建议受到质疑,一些研究显示 NCS 结果后患结直肠癌(CRC)的风险持续降低:目的:根据基于主要人口统计学和生活方式风险因素的风险评分,研究NCS结果(即未发现CRC或息肉)后的长期CRC发病率和死亡率:在这项队列研究中,从 1988 年和 1991 年到 2020 年,对来自护士健康研究(Nurses' Health Study)、护士健康研究 II(Nurses' Health Study II)和卫生专业人员随访研究(Health Professionals Follow-up Study)的 3 个前瞻性美国人群队列进行了随访。2017年1月1日至2018年12月31日周期的美国国家健康与营养调查(NHANES)数据被用来与美国普通人群的风险分布进行比较。数据分析从2023年10月至2024年8月进行:NCS结果和风险评分的时变状态.主要结果和测量指标:采用 Cox 比例危险回归法计算 CRC 发病率和死亡率的危险比(HRs)和 95% CIs:共有 195 453 名参与者(基线年龄中位数[IQR]为 44 [37-56] 岁;81% 为女性)接受了中位数(IQR)为 12 (6-20) 年的随访。在 81 151 名获得 NCS 结果的患者和 114 302 名未获得内镜检查结果的患者中,分别记录了 394 例和 2229 例 CRC 病例以及 167 例和 637 例 CRC 死亡病例。结肠镜筛查结果呈阴性与 20 年内较低的 CRC 发病率(HR,0.51;95% CI,0.44-0.58)和死亡率(HR,0.56;95% CI,0.46-0.70)持续相关。在有 NCS 结果的人群中,中度风险(6-7 分)和低度风险(0-5 分)人群的 10 年累积 CRC 发病率(0.78%)分别在初筛后 16 年和 25 年才达到高风险人群(8-12 分)的水平:这些研究结果为患者和医生共同决策提供了证据,即考虑将 NCS 结果后的再筛查间隔时间延长至目前建议的 10 年以上,特别是对于低风险人群。作为概念验证,这些结果表明,在决定进行结肠镜再筛查时,考虑已知的 CRC 风险因素非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Jama Oncology
Jama Oncology Medicine-Oncology
CiteScore
37.50
自引率
1.80%
发文量
423
期刊介绍: At JAMA Oncology, our primary goal is to contribute to the advancement of oncology research and enhance patient care. As a leading journal in the field, we strive to publish influential original research, opinions, and reviews that push the boundaries of oncology science. Our mission is to serve as the definitive resource for scientists, clinicians, and trainees in oncology globally. Through our innovative and timely scientific and educational content, we aim to provide a comprehensive understanding of cancer pathogenesis and the latest treatment advancements to our readers. We are dedicated to effectively disseminating the findings of significant clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our ultimate objective is to facilitate the translation of new knowledge into tangible clinical benefits for individuals living with and surviving cancer.
期刊最新文献
Targeting CNS Metastases in Non-Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers: A Review. Colorectal Cancer Incidence and Mortality After Negative Colonoscopy Screening Results. Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance. Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1